MetaCap

BridgeBio Oncology Therapeutics (BBOT) vs Sionna Therapeutics (SION)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BridgeBio Oncology Therapeutics (BBOT) has outperformed Sionna Therapeutics (SION) over the past year, losing 85.4% versus a loss of 93.5%. BridgeBio Oncology Therapeutics is the larger company by market cap ($145.3 million vs $127.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BBOT-85.39%SION-93.53%
+22%-38%-99%
Nov 21, 20251 yearNov 20, 2026
BBOT-83.24%SION-88.70%
+114%+8%-98%
Feb 3, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BBOT versus SION key metrics
MetricBBOTSION
Share price$1.81$2.83
Market cap$145.25M$127.79M
1-day change-2.69%-4.88%
YTD return-85.54%-93.13%
1-year return-85.39%-93.53%
P/E ratio (TTM)3.42—
EPS (TTM)$0.53$-2.43
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-134.04M$-75.27M
52-week high$14.87$54.97
52-week low$1.79$2.75
Distance from 52-week high-87.83%-94.86%
Analyst consensusstrong_buyhold
Avg. price target upside+1060.22%+643.36%
Average volume631.56K1.12M
Shares outstanding80.25M45.24M
Employees9259
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About BridgeBio Oncology Therapeutics

BBOT stock →

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.

Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees

About Sionna Therapeutics

SION stock →

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.

Health Care · Biotechnology: Pharmaceutical Preparations · 59 employees

BBOT vs SION FAQ

Which is bigger, BridgeBio Oncology Therapeutics or Sionna Therapeutics?

BridgeBio Oncology Therapeutics (BBOT) is larger, with a market capitalization of $145.25M compared with $127.79M for Sionna Therapeutics (SION).

Which stock has performed better over the past year, BBOT or SION?

BBOT returned -85.39% over the past 12 months, compared with -93.53% for SION (price return, excluding dividends). Past performance does not predict future results.

Are BridgeBio Oncology Therapeutics and Sionna Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons